Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that nine posters on ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection will be available online during and after the 11 th Annual Congress on Controversies in Ophthalmology (COPHy) conference beginnin
March 25, 2020
· 3 min read